A large global biopharmaceutical manufacturer achieved 200% ROI in the first month after implementing Review by Exception (RBE). Before RBE, batch release took 3–4 weeks; after, batches released in hours. Digitizing batch release can reduce overall cycle time by more than 90%.
Manual review bottleneck — "every batch treated like high-risk one; backlog builds fast" — is the core problem. Re-keying and transcription errors break data integrity. Releasing lots while OOS/OOT investigations remain open creates regulatory exposure.
Automated review and release of production batches by verifying all quality criteria are met — in-process checks, final inspection, test results, environmental data — before distribution. Generates Certificates of Analysis (CoA) and Certificates of Conformance (CoC). The most dependency-heavy operational capability in the tree.
Review by Exception (RBE). ISPE defines RBE as "an approach in which manufacturing and quality data are screened to present or report only critical process exceptions." RBE reduces 150-page batch record reviews to a 3-page exception report. CoA automation delivers 30–70% faster lot release with near-zero documentation deviations from manual entry. One pharma QC lab achieved 30% reduction in manual data entry and 40% faster CoA generation after LIMS implementation.
EU Qualified Person batch release. EU GMP Annex 16 requires certification by a Qualified Person (QP) before any batch enters the EU market. The three-stage process covers checks of manufacture/testing, QP review/confirmation, and certification recorded in a QP register. Annex 16 specifically allows validated computerized systems to prevent un-certified batches from entering saleable stock. For imports from third countries, QPs must ensure full qualitative and quantitative analysis of active substances conducted in a Member State unless a Mutual Recognition Agreement exists. Parametric release — based on validated process parameters rather than end-product testing — represents the highest maturity level.
AI-assisted batch review. Progressive maturity model: basic rule-based exception detection → statistical process monitoring → ML-driven predictive quality. AI identifies anomalies in batch data, forecasts potential exceptions before they occur, parses jurisdictional regulations for QP support, and identifies correlations between exceptions across batches.
LIMS (Laboratory Information Management Systems) with automatic CoA generation, MES with batch record management and RBE capability, QMS batch release modules, AI-assisted exception detection engines, QP certification workflow platforms.
EU GMP Annex 16, FDA 21 CFR 211.192 (production record review), ISO 9001:2015 Clause 8.6, FDA 21 CFR Part 11, EU GMP Annex 11, ICH Q7.
Version-controlled creation, approval, distribution, and retirement of SOPs with immutable audit trail, electronic signatures, and access controls.
Batch release procedures and CoA templates must be controlled documents.
Capturing, classifying, investigating, and dispositioning nonconforming materials or process deviations with structured ten-step workflow and.
Open deviations must be resolved or dispositioned before batch release can proceed.
Tracking, scheduling, and documenting calibration of all measurement instruments with MSA studies to validate measurement system integrity for.
Test instruments must be calibrated and validated before results are release-worthy.
Nothing downstream yet.
Your brand here — Reach our audience of professional directory owners and boost your sales.